Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000152840 | SCV000202236 | uncertain significance | not provided | 2014-03-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001850086 | SCV002294917 | uncertain significance | Bardet-Biedl syndrome | 2022-02-19 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 329 of the BBS4 protein (p.Ala329Val). This variant is present in population databases (rs201987100, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with BBS4-related conditions. ClinVar contains an entry for this variant (Variation ID: 166735). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002483324 | SCV002790237 | uncertain significance | Bardet-Biedl syndrome 4 | 2021-11-30 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004748603 | SCV005359803 | uncertain significance | BBS4-related disorder | 2024-03-11 | no assertion criteria provided | clinical testing | The BBS4 c.986C>T variant is predicted to result in the amino acid substitution p.Ala329Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0065% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |